PLEKHG4B

Summary

PLEKHG4B (pleckstrin homology and RhoGEF domain containing G4B, HGNC:29399) is a protein-coding gene on chromosome 5p15.33, encoding Pleckstrin homology domain-containing family G member 4B (Q96PX9). Guanine nucleotide exchange factor (GEF) which specifically activates small GTPase CDC42 by exchanging bound GDP for free GTP.

This gene encodes a large protein that contains a pleckstrin homology domain and may function as a guanine nucleotide exchange factor.

Source: NCBI Gene 153478 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 315 total
• MANE Select transcript: NM_052909

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29399
Approved symbol	PLEKHG4B
Name	pleckstrin homology and RhoGEF domain containing G4B
Location	5p15.33
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1909, ARHGEF48
Ensembl gene	ENSG00000153404
Ensembl biotype	protein_coding
OMIM	620665
Entrez	153478

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 retained_intron

ENST00000283426, ENST00000502646, ENST00000504041, ENST00000637938, ENST00000924299, ENST00000924300, ENST00000924301

RefSeq mRNA: 1 — MANE Select: NM_052909 NM_052909

CCDS: CCDS34124

Canonical transcript exons

ENST00000637938 — 20 exons

Exon	Start	End
ENSE00001010580	169340	169592
ENSE00001083898	143047	143256
ENSE00001091609	162722	163548
ENSE00001135995	156071	156210
ENSE00001136002	155345	155443
ENSE00001136007	154875	154991
ENSE00001136016	151513	151599
ENSE00001136025	144827	144920
ENSE00001136029	143380	143503
ENSE00001198672	161783	161944
ENSE00001279274	156773	156911
ENSE00001312287	182004	189966
ENSE00002031980	113251	113448
ENSE00002040385	92168	92276
ENSE00002058692	139483	140716
ENSE00003495568	171043	171132
ENSE00003541475	181514	181675
ENSE00003585064	173918	174098
ENSE00003635388	171214	171444
ENSE00003688124	172897	173067

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 82.63.

FANTOM5 (CAGE): breadth broad, TPM avg 2.1281 / max 73.3602, expressed in 455 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
55435	2.0145	440
55437	0.1136	52

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	82.63	gold quality
amniotic fluid	UBERON:0000173	80.81	gold quality
ganglionic eminence	UBERON:0004023	79.19	gold quality
buccal mucosa cell	CL:0002336	79.15	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.82	gold quality
cortical plate	UBERON:0005343	76.12	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.48	gold quality
cerebellar vermis	UBERON:0004720	74.13	silver quality
upper arm skin	UBERON:0004263	71.71	gold quality
thyroid gland	UBERON:0002046	71.40	gold quality
left lobe of thyroid gland	UBERON:0001120	71.17	gold quality
right lobe of thyroid gland	UBERON:0001119	70.97	gold quality
pituitary gland	UBERON:0000007	70.89	gold quality
myocardium	UBERON:0002349	70.35	gold quality
adenohypophysis	UBERON:0002196	69.63	gold quality
pancreatic ductal cell	CL:0002079	69.00	silver quality
kidney epithelium	UBERON:0004819	68.67	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	68.59	gold quality
bronchial epithelial cell	CL:0002328	67.91	gold quality
bronchus	UBERON:0002185	67.61	gold quality
epithelial cell of pancreas	CL:0000083	67.55	gold quality
cartilage tissue	UBERON:0002418	67.51	gold quality
sperm	CL:0000019	67.06	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	66.73	gold quality
left ventricle myocardium	UBERON:0006566	66.67	gold quality
right uterine tube	UBERON:0001302	66.60	gold quality
cardiac muscle of right atrium	UBERON:0003379	66.47	gold quality
minor salivary gland	UBERON:0001830	65.68	gold quality
mouth mucosa	UBERON:0003729	64.97	gold quality
pericardium	UBERON:0002407	64.80	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ENAD-17	no	54.30
E-MTAB-6075	no	9.96
E-ANND-3	no	4.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

255 targeting PLEKHG4B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-23A-5P	99.94	65.39	468
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-221-5P	99.86	65.45	1052

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-269k10.2	ENSDARG00000086950

Paralogs (22): TRIO (ENSG00000038382), MCF2L2 (ENSG00000053524), PLEKHG2 (ENSG00000090924), MCF2 (ENSG00000101977), ARHGEF7 (ENSG00000102606), PLEKHG1 (ENSG00000120278), MCF2L (ENSG00000126217), ARHGEF6 (ENSG00000129675), ARHGEF9 (ENSG00000131089), VAV3 (ENSG00000134215), VAV1 (ENSG00000141968), TIAM2 (ENSG00000146426), KIAA1755 (ENSG00000149633), TIAM1 (ENSG00000156299), KALRN (ENSG00000160145), VAV2 (ENSG00000160293), ARHGEF40 (ENSG00000165801), SPATA13 (ENSG00000182957), SESTD1 (ENSG00000187231), PLEKHN1 (ENSG00000187583), PLEKHG4 (ENSG00000196155), ARHGEF25 (ENSG00000240771)

Protein

Protein identifiers

Pleckstrin homology domain-containing family G member 4B — Q96PX9 (reviewed: Q96PX9)

All UniProt accessions (3): Q96PX9, A0AAK2PKJ8, Q96HN1

UniProt curated annotations — full annotation on UniProt →

Function. Guanine nucleotide exchange factor (GEF) which specifically activates small GTPase CDC42 by exchanging bound GDP for free GTP. Plays a role in actin cytoskeletal remodeling in the late stage of cell-cell junction formation by regulating the contractility of actin filaments, which prompts the conversion from ‘open’ to ‘closed’ junctions.

Subunit / interactions. Found in a complex with ARHGEF11 and ARHGEF12; binding to ARHGEF11 and ARHGEF12 enhances CDC42 GEF activity of PLEKHG4B, and PLEKHG4B, in turn, inhibits ARHGEF11- and ARHGEF12-mediated RHOA activation. Interacts with ANXA2; this interaction is required for PLEKHG4B localization to cell-cell adhesions.

Subcellular location. Basal cell membrane. Cell junction. Nucleus. Cytoplasm.

Domain organisation. Subjects to autoinhibition, mediated by the N-terminal domain.

RefSeq proteins (1): NP_443141* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000219	DH_dom	Domain
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR035899	DBL_dom_sf	Homologous_superfamily
IPR052231	Rho_GEF_signaling-related	Family
IPR055251	SOS1_NGEF_PH	Domain

Pfam: PF00621, PF22697

UniProt features (31 total): compositionally biased region 11, sequence variant 8, region of interest 7, domain 2, chain 1, mutagenesis site 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96PX9-F1	59.46	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
1373	does not localize to the basal membrane nor accumulate at cell-cell junctions in ionomycin-treated cells. does not affec

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9013148	CDC42 GTPase cycle

MSigDB gene sets: 63 (showing top): GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_NEUROGENESIS, GOBP_CELL_CELL_ADHESION, NIKOLSKY_BREAST_CANCER_5P15_AMPLICON, GOBP_CELL_PROJECTION_ORGANIZATION, CERVERA_SDHB_TARGETS_1_UP, GOCC_CELL_CELL_JUNCTION, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOMF_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY, GOCC_ANCHORING_JUNCTION, GOCC_PLASMA_MEMBRANE_REGION, GOCC_EXTRINSIC_COMPONENT_OF_MEMBRANE, GOCC_BASAL_PART_OF_CELL, WANG_SMARCE1_TARGETS_UP, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY

GO Biological Process (3): axon guidance (GO:0007411), regulation of small GTPase mediated signal transduction (GO:0051056), cell-cell adhesion (GO:0098609)

GO Molecular Function (2): guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (9): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), cell-cell junction (GO:0005911), basal plasma membrane (GO:0009925), extrinsic component of membrane (GO:0019898), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
membrane	2
axonogenesis	1
neuron projection guidance	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
cell adhesion	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1
cell periphery	1
anchoring junction	1
basal part of cell	1
plasma membrane region	1
cell junction	1

Protein interactions and networks

STRING

392 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLEKHG4B	ARHGEF19	Q8IW93	520
PLEKHG4B	LRRC14B	A6NHZ5	480
PLEKHG4B	LRRC20	Q8TCA0	477
PLEKHG4B	ARHGEF11	O15085	444
PLEKHG4B	ARHGEF33	A8MVX0	424
PLEKHG4B	OR13F1	Q8NGS4	418
PLEKHG4B	DRC11L	A6NCM1	418
PLEKHG4B	RASGRF2	O14827	405
PLEKHG4B	CNN1	P51911	400
PLEKHG4B	OR10G4	Q8NGN3	400
PLEKHG4B	PLEKHG6	Q3KR16	396
PLEKHG4B	LRRC30	A6NM36	392
PLEKHG4B	ARHGEF38	Q9NXL2	391
PLEKHG4B	ARHGEF15	O94989	379
PLEKHG4B	ATP6V1D	Q9Y5K8	376

IntAct

17 interactions, top by confidence:

A	B	Type	Score
ARHGEF11	PLEKHG4B	psi-mi:“MI:0915”(physical association)	0.500
ARHGEF12	PLEKHG4B	psi-mi:“MI:0915”(physical association)	0.500
PLEKHG4B	ARHGEF11	psi-mi:“MI:0914”(association)	0.500
FHL3	PLEKHG4B	psi-mi:“MI:0915”(physical association)	0.490
GLRX3	PLEKHG4B	psi-mi:“MI:0915”(physical association)	0.490
PLEKHG4B	FHL3	psi-mi:“MI:0915”(physical association)	0.490
PLEKHG4B	Arhgap18	psi-mi:“MI:0915”(physical association)	0.400
KPNA4	PLEKHG4B	psi-mi:“MI:0915”(physical association)	0.400
PLEKHG4B	GNA13	psi-mi:“MI:0914”(association)	0.350
ARHGEF11	MTX2	psi-mi:“MI:0914”(association)	0.350
PLEKHG4B	ARHGEF11	psi-mi:“MI:0914”(association)	0.350
ARHGEF40	ARHGEF11	psi-mi:“MI:0914”(association)	0.350
ARHGEF12	GIPC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (35): PLEKHG4B (Affinity Capture-RNA), PLEKHG4B (Two-hybrid), PLEKHG4B (Two-hybrid), ARHGEF11 (Affinity Capture-Western), ARHGEF12 (Affinity Capture-Western), PLEKHG4B (Reconstituted Complex), ARHGAP18 (Affinity Capture-Western), PLEKHG4B (FRET), PLEKHG4B (Affinity Capture-MS), PLEKHG4B (Affinity Capture-MS), PLEKHG4B (Affinity Capture-MS), ARHGAP18 (Affinity Capture-MS), ARHGEF11 (Affinity Capture-MS), ARHGEF12 (Affinity Capture-MS), CSTA (Affinity Capture-MS)

ESM2 similar proteins: A0A5F9ZHS7, A1YGK1, A2T7E6, A8MZG2, O08574, O43593, O60393, O75593, O88621, O95231, P0C1T1, P0CG20, P20428, P97609, Q04667, Q17QR5, Q2KIS6, Q2M1V0, Q2T9Q7, Q32LE6, Q497V6, Q5JUK2, Q5M844, Q5RJB0, Q5TGS1, Q61645, Q61657, Q6ZMY3, Q6ZN32, Q6ZNG2, Q7RTU1, Q8BZW2, Q8CGW9, Q8IWN7, Q8IXT2, Q8IZ20, Q8N1L9, Q8N7G0, Q8N944, Q8N9Y4

Diamond homologs: A2ASS6, A2CG49, A4IFM7, A8C984, A8WXF6, E9PT87, F1M0Z1, G4SLH0, O02827, O08875, O43293, O44997, O54784, O60229, O62305, O70150, O75962, O88764, O94768, O94806, P07313, P08414, P10911, P13234, P18652, P18653, P18654, P20689, P22216, P25323, P29294, P51812, P53355, P97924, Q00168, Q0KHT7, Q0KL02, Q14012, Q15139, Q15418

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PLEKHG4B	“up-regulates activity”	CDC42	“guanine nucleotide exchange factor”

Disease & clinical

Clinical variants and AI predictions

ClinVar

315 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	256
Likely benign	31
Benign	10

Top pathogenic / likely-pathogenic (0)

SpliceAI

3668 predictions. Top by Δscore:

Variant	Effect	Δscore
5:143046:GAC:G	acceptor_gain	1.0000
5:143252:CCCAG:C	donor_loss	1.0000
5:143253:CCAGG:C	donor_loss	1.0000
5:143254:CAG:C	donor_loss	1.0000
5:143255:AGGT:A	donor_loss	1.0000
5:143256:GG:G	donor_loss	1.0000
5:143258:T:G	donor_loss	1.0000
5:154873:A:AG	acceptor_gain	1.0000
5:154874:G:GG	acceptor_gain	1.0000
5:154874:GT:G	acceptor_gain	1.0000
5:155333:A:AG	acceptor_gain	1.0000
5:155340:A:AG	acceptor_gain	1.0000
5:155343:A:AG	acceptor_gain	1.0000
5:155344:G:GG	acceptor_gain	1.0000
5:156065:GTGCA:G	acceptor_loss	1.0000
5:156067:GCA:G	acceptor_loss	1.0000
5:156068:CA:C	acceptor_loss	1.0000
5:156069:A:AC	acceptor_loss	1.0000
5:156070:G:GT	acceptor_loss	1.0000
5:156070:GGAA:G	acceptor_gain	1.0000
5:156207:GCCG:G	donor_gain	1.0000
5:156209:CGG:C	donor_loss	1.0000
5:156210:GGTGA:G	donor_loss	1.0000
5:156211:G:GG	donor_gain	1.0000
5:156211:GT:G	donor_loss	1.0000
5:156212:T:A	donor_loss	1.0000
5:156768:CTCAG:C	acceptor_loss	1.0000
5:156770:CA:C	acceptor_loss	1.0000
5:156771:A:AG	acceptor_gain	1.0000
5:156771:AG:A	acceptor_gain	1.0000

AlphaMissense

10579 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:173978:T:C	F1072L	0.997
5:173980:T:A	F1072L	0.997
5:173980:T:G	F1072L	0.997
5:173966:T:C	F1068L	0.996
5:173968:T:A	F1068L	0.996
5:173968:T:G	F1068L	0.996
5:173979:T:C	F1072S	0.995
5:173967:T:C	F1068S	0.994
5:172981:T:C	F1023L	0.993
5:172983:C:A	F1023L	0.993
5:172983:C:G	F1023L	0.993
5:173008:A:C	S1032R	0.993
5:173010:C:A	S1032R	0.993
5:173010:C:G	S1032R	0.993
5:172940:T:C	F1009S	0.992
5:172997:T:C	L1028P	0.992
5:173006:T:C	F1031S	0.992
5:174047:T:A	W1095R	0.992
5:174047:T:C	W1095R	0.992
5:172987:T:C	F1025L	0.991
5:172989:T:A	F1025L	0.991
5:172989:T:G	F1025L	0.991
5:173005:T:C	F1031L	0.991
5:173007:T:A	F1031L	0.991
5:173007:T:G	F1031L	0.991
5:172982:T:C	F1023S	0.990
5:173000:T:A	I1029N	0.990
5:173067:G:C	K1051N	0.990
5:173067:G:T	K1051N	0.990
5:173973:T:C	I1070T	0.990

dbSNP variants (sampled 300 via entrez): RS1000027937 (5:156841 C>T), RS1000029389 (5:92148 G>A), RS1000035270 (5:132502 C>G), RS1000061293 (5:118529 A>G), RS1000077255 (5:97629 G>A), RS1000088061 (5:167216 G>A,C), RS1000116120 (5:187889 G>A), RS1000123220 (5:173507 T>C), RS1000171239 (5:115654 C>G), RS1000194894 (5:154488 C>T), RS1000195584 (5:189439 C>G,T), RS1000227497 (5:154778 C>G,T), RS1000358503 (5:185128 G>A), RS1000367949 (5:104894 A>G), RS1000369576 (5:179809 A>T)

Disease associations

OMIM: gene MIM:620665 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003832_19	Asthma (childhood onset)	8.000000e-06
GCST003832_3	Asthma (childhood onset)	1.000000e-06
GCST009309_10	Face memory	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression, decreases expression	5
trichostatin A	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Aflatoxin B1	affects methylation, increases methylation	2
aristolochic acid I	increases expression	1
bisphenol F	increases methylation, affects cotreatment	1
methylmercuric chloride	decreases expression	1
bisphenol A	increases methylation	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases abundance, increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Aflatoxins	increases expression	1
Aldehydes	increases expression	1
Cadmium	decreases expression, increases abundance	1
Copper	decreases expression, affects cotreatment	1
Glucose	increases expression	1
Manganese	increases expression, increases abundance	1
Methapyrilene	increases methylation	1
Phthalic Acids	decreases methylation	1
Smoke	increases expression	1
Thiram	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer